Genitourinary Radiology: Page 13

MRI after PSA testing is more cost-effective than standard protocol
By Kate Madden Yee
Prostate cancer screening that combines prostate-specific antigen (PSA) testing followed by an MRI is more cost-effective than the traditional pathway of PSA to standard biopsy, according to a study published November 10 in JAMA Oncology.
November 10, 2022
2021 07 09 15 14 8529 Mri Prostate 400
Blue Earth moves toward U.K. prostate radiopharmaceutical licensing
By AuntMinnie.com staff writers
Blue Earth Therapeutics has secured an "innovation passport" from the U.K.'s Innovative Licensing and Access Pathway for its investigational therapeutic radiopharmaceutical lutetium-177 rhPSMA-10.1 for treatment of metastatic prostate cancer.
November 8, 2022
2017 01 26 12 32 44 153 Check Mark 400
Telix highlights kidney cancer imaging study results
By AuntMinnie.com staff writers
Telix Pharmaceuticals is highlighting positive clinical results from a study that has tested its investigational kidney cancer PET imaging agent, TLX250-CDx.
November 6, 2022
2018 10 18 23 20 1387 Liver Cancer 400
Week in review: CT or ultrasound for kidney stones? | Final 2023 Medicare reimbursement rules | PET/CT for melanoma
By Erik L. Ridley
November 4, 2022
PSMA-PET improves radical prostate surgery
By Will Morton
PET imaging with prostate-specific antigen (PSMA) radiotracers can help surgeons spare nerves in patients undergoing radical prostatectomy, according to a study published November 1 in Urologic Oncology.
November 1, 2022
2022 11 01 23 31 4332 2022 11 02 Psma Pet 20221101235842
Which is better for diagnosing kidney stones, CT or ultrasound?
By Kate Madden Yee
CT is the dominant imaging tool in the emergency department for diagnosing and evaluating kidney stones, but it may not be the best, according to a research letter published October 31 in JAMA Internal Medicine.
November 1, 2022
2016 08 23 17 04 30 620 Kidney 400
Breast, prostate cancer diagnoses still lag after pandemic
By AuntMinnie.com staff writers
The number of diagnoses of breast and prostate cancer still remain significantly below levels reached prior to the COVID-19 pandemic, according to research from Quest Diagnostics published October 10 in the Journal of Clinical Oncology (JCO) Clinical Cancer Informatics.
October 10, 2022
2022 10 11 19 12 6538 Cancer Cell Yellow 400
RSIP Vision ships AI tool for 3D ureter reconstruction
By AuntMinnie.com staff writers
Artificial intelligence (AI) software developer RSIP Vision has introduced software that can provide 3D reconstructions of 2D fluoroscopic images of the ureter.
October 3, 2022
2021 07 16 16 27 9194 Artificial Intelligence Ai Abstract 400
NTT Data completes validation of kidney AI algorithm
By AuntMinnie.com staff writers
NTT Data has validated its MaestroAI artificial intelligence (AI) software for the indication of kidney localization and abnormalities detection.
October 2, 2022
2021 03 11 21 54 5662 Computer Ai Artificial Illustration 400
China OKs study of Telix PET radiotracer for kidney cancer
By AuntMinnie.com staff writers
Telix Pharmaceuticals has received approval in China for a study of its investigational TLX250-CDx radiotracer for PET imaging of renal cancer.
September 27, 2022
2016 08 23 17 04 30 620 Kidney 400
Blue Earth wins FDA nod for PSMA-PET tracer NDA
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) from Blue Earth Diagnostics for its investigational radiohybrid prostate-specific membrane antigen (PSMA) F-18 rhPSMA-7.3 radiopharmaceutical.
September 26, 2022
2022 09 27 21 29 9234 2022 09 26 Blue Earth 20220927211614
Insurance coverage for prostate MRI is inconsistent across the U.S.
By Kate Madden Yee
Insurance coverage for prostate MRI is inconsistent across the U.S., which may contribute to unequal access to the technology for patients, according to a study published September 7 in the American Journal of Roentgenology.
September 8, 2022
2021 07 09 15 14 8529 Mri Prostate 400
Previous Page
Page 13 of 96
Next Page